Author: Florian Stieglitz, Market Access Consultant Faced with increasing complexity from internal organisational restructuring that created frictions around decision making […]
Author: Tim Ebbecke, Senior Consultant The GKV Financial Stabilisation Act (GKV-FinStG) was intended to bring far-reaching changes to Germany as
In this comprehensive report, Kintiga explores the strategic implications of this legislation for market access in Germany. Why now? Pharmaceutical
Faced with regulatory rejection in Europe despite FDA approval, a US-based pharmaceutical company turned to Kintiga to reframe its product’s
Author: Marianne Lambertson, Chief Commercial Officer As the United States undergoes significant shifts in healthcare policy under the new administration,
What is the NICE severity modifier? Author: Ben Barron-Millar, Senior Consultant In 2022, National Institute for Health and Care Excellence
EU HTA: One HTA Regulation for All The strategic perspective on EU HTA from the Kintiga team For a deeper
Author: Florian Stieglitz, Consultant The 12th edition of the AMNOG Report, recently published by DAK-Gesundheit, arrives at a decisive moment
Date: Tuesday 10 June 2025 Time: 13:00 – 14:00 BST Location: Online As the United States undergoes significant shifts in
Author: Steve Glass , Group Chief Executive Officer This week, President Donald Trump signed a sweeping executive order that has
